Zura Bio (ZURA)

Executive Summary

Zura Bio is a clinical-stage biopharmaceutical company focused on developing novel antibody-based therapies for severe autoimmune and inflammatory diseases. Founded in 2022 and headquartered in San Diego, the company went public in 2024 (NASDAQ: ZURA) and is advancing its lead asset, tibulizumab, a humanized bispecific antibody that simultaneously targets BAFF and IL-17A—two key drivers of autoimmune pathology. Tibulizumab is currently being evaluated in two Phase 2 trials: one for hidradenitis suppurativa (HS) and another for systemic sclerosis (SSc). Both trials are actively recruiting, with HS completion expected in April 2027 and SSc completion in January 2028. Zura Bio’s strategy is to leverage tibulizumab’s dual mechanism to potentially improve efficacy over single-target biologics in indications with high unmet need. The company has no approved products and is still in early stages, with significant binary risk tied to upcoming clinical data.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data for tibulizumab in hidradenitis suppurativa (HS)45% success
• Q4 2027Phase 2 top-line data for tibulizumab in systemic sclerosis (SSc)30% success